A Phase 1/2 Study of Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Patients With Relapsed/Refractory Multiple Myeloma
This study is currently recruiting participants.
Verified August 2012 by Oncotherapeutics
Sponsor:
Oncotherapeutics
Collaborator:
Celgene Corporation
Information provided by (Responsible Party):
Oncotherapeutics
ClinicalTrials.gov Identifier:
NCT01541332
First received: February 20, 2012
Last updated: May 6, 2013
Last verified: August 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study is currently recruiting participants. |
|---|---|
| Estimated Study Completion Date: | April 2014 |
| Estimated Primary Completion Date: | February 2014 (Final data collection date for primary outcome measure) |